CN113832069B - Clostridium butyricum and application thereof - Google Patents
Clostridium butyricum and application thereof Download PDFInfo
- Publication number
- CN113832069B CN113832069B CN202111200171.5A CN202111200171A CN113832069B CN 113832069 B CN113832069 B CN 113832069B CN 202111200171 A CN202111200171 A CN 202111200171A CN 113832069 B CN113832069 B CN 113832069B
- Authority
- CN
- China
- Prior art keywords
- clostridium butyricum
- choline
- dopamine
- gamma
- neurotransmitters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000193171 Clostridium butyricum Species 0.000 title claims abstract description 108
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 126
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 122
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 65
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 63
- 229960003638 dopamine Drugs 0.000 claims abstract description 61
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 59
- 229960001231 choline Drugs 0.000 claims abstract description 55
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 55
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229960002989 glutamic acid Drugs 0.000 claims abstract description 41
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 40
- 239000004220 glutamic acid Substances 0.000 claims abstract description 40
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 25
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 229960004441 tyrosine Drugs 0.000 claims abstract description 14
- 238000004321 preservation Methods 0.000 claims abstract description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960004373 acetylcholine Drugs 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229960003080 taurine Drugs 0.000 claims abstract description 11
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960003732 tyramine Drugs 0.000 claims abstract description 10
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims abstract description 10
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229940049906 glutamate Drugs 0.000 claims description 7
- 229930195712 glutamate Natural products 0.000 claims description 7
- 239000006041 probiotic Substances 0.000 claims description 7
- 235000018291 probiotics Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000000855 fermentation Methods 0.000 abstract description 28
- 230000004151 fermentation Effects 0.000 abstract description 28
- 239000003674 animal food additive Substances 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 239000000306 component Substances 0.000 description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 12
- 240000008042 Zea mays Species 0.000 description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 12
- 235000005822 corn Nutrition 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 235000010633 broth Nutrition 0.000 description 10
- 239000002054 inoculum Substances 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 description 9
- 235000019764 Soybean Meal Nutrition 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000004455 soybean meal Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000013028 medium composition Substances 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 241000193403 Clostridium Species 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 229960004799 tryptophan Drugs 0.000 description 6
- 239000000273 veterinary drug Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 235000013923 monosodium glutamate Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 229940073490 sodium glutamate Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 210000003736 gastrointestinal content Anatomy 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 240000001606 Adenanthera pavonina Species 0.000 description 2
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 241000252210 Cyprinidae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007399 clostridium medium Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007692 rcm medium Substances 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- ZMQBAPPSYGILGT-UHFFFAOYSA-N sodium;2,3-bis(hydroxymethyl)butanedioic acid Chemical compound [Na+].OCC(C(O)=O)C(CO)C(O)=O ZMQBAPPSYGILGT-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/14—Glutamic acid; Glutamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to clostridium butyricum and application, medicine, food, health care product, veterinary medicine, feed additive and microecological preparation thereof, and belongs to the technical field of microorganisms. The clostridium butyricum of the invention is classified and named as clostridium butyricum (Clostridium butyricum) F06, and the preservation number is CCTCC NO: m2019962. The clostridium butyricum can be applied to producing neurotransmitter substances such as gamma-aminobutyric acid, dopamine, glutamic acid, choline, acetylcholine, L-tryptophan, tyrosine, taurine, acetylcholine, tyramine and the like. After fermentation conditions are optimized, the contents of gamma-aminobutyric acid, dopamine, glutamic acid and choline in clostridium butyricum fermentation liquid respectively reach 4.78g/L,5.82g/L,135.9g/L and 3.78g/L, and clostridium butyricum can be applied to producing neurotransmitter substances and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to clostridium butyricum and application thereof.
Background
Gamma-aminobutyric acid is an important neurotransmitter in the central nervous system, is a naturally occurring non-protein constituent amino acid, has extremely important physiological functions, can promote the activation of brain, strengthen brain and improve intelligence, resist epilepsy, promote sleep, beautify and moisten skin, delay the aging function of brain, supplement human body inhibitory neurotransmitter, and has good blood pressure reducing effect. Secondly, it can also promote renal function improvement and protection. Inhibit fatty liver and obesity, and activate liver function. The daily supplementation of trace gamma-aminobutyric acid is beneficial to relieving heart and brain blood pressure, promoting the balance of amino acid metabolism in human body and regulating immune function.
Glutamate is an excitatory neurotransmitter, and brain tissue can only oxidize glutamate, but not other amino acids, so glutamate can be used as an energy substance for brain tissue to improve and maintain brain function. Glutamic acid is used as a supplement to the nerve center and cerebral cortex. Glutamate can promote peristalsis of the digestive tract. Dopamine plays an important role in motor control, and parkinson's disease is caused by severe dopamine reduction caused by dopaminergic neuronal degeneration. The limbic dopamine system and the mesocortical dopamine system are widely believed to play a role in learning and memory. It has been reported that the dopaminergic neurons of the monkey a10 region are involved in the learning of transient changes in basic attention and impulsive activity during motivation in cognitive behavior. The fact that cognitive function will decline with age is well documented in both humans and primates. In recent years, studies have provided direct evidence that demonstrates the obvious correlation between reduced dopamine function, reduced cognitive function and brain aging, and comparative studies have been performed on volunteers of the same age, which have shown that dopamine levels are positively correlated with cognitive function. Studies have shown that mood depression, low pleasure, low mood, and low dopamine levels.
Choline is a precursor of acetylcholine in all biological membrane components and cholinergic neurons. The choline can promote brain development and improve memory capacity, ensure information transmission, regulate apoptosis, prevent cholesterol deposition on the inner wall of blood vessel and remove partial sediment, and improve fat absorption and utilization, so that the choline has the effect of preventing cardiovascular diseases.
Neurotransmitters such as gamma-aminobutyric acid, glutamic acid, dopamine and choline can be converted and obtained under the catalytic action of various enzymes in the body, but under the conditions of aging, stress state, intestinal microecological disorder, diseases or high mental stress, the synthesis of neurotransmitters (gamma-aminobutyric acid, glutamic acid, dopamine and choline and the like) in the body is obviously reduced, so that the phenomenon of deficiency occurs. Exogenous neurotransmitter addition can improve the condition of insufficient synthesis of endogenous neurotransmitter, and promote body health. It is also possible to produce neurotransmitters in the intestine for direct absorption and utilization by supplementing the functional probiotics. Therefore, development of foods, health products, feeds or microecological additives rich in neurotransmitters (gamma-aminobutyric acid, dopamine, glutamic acid, choline, etc.) has become a hot spot of research.
The health food has been developed from rice germ in japan, has remarkable effects in improving insomnia, depression, climacteric syndrome, etc., and is widely added to various foods such as beverages, jams, and pastries. However, the rice germ has low content, and the rice germ can reach high content only by separation and concentration, thereby restricting the application of the rice germ. Therefore, the development of beneficial microorganisms by biotechnology and the production of foods, health products or feeds rich in gamma-aminobutyric acid and additives thereof by the beneficial microorganisms are key technologies for solving the problem. The application numbers CN201910502771.3 and CN201711386926.9 both disclose a streptococcus thermophilus with high gamma-aminobutyric acid yield. Application number CN201910502750.1 discloses a lactococcus lactis subspecies lactis with high yield of gamma-aminobutyric acid. The application number CN201910274454.0 discloses lactobacillus rhamnosus with high yield of gamma-aminobutyric acid. The application number CN201610964033.7 discloses a lactobacillus plantarum producing gamma-aminobutyric acid. Application number CN201611003216.9 discloses a strain of Lactobacillus pentosus producing gamma-aminobutyric acid. Application number CN201710149052.9 discloses rhizopus oryzae with high yield of gamma-aminobutyric acid. Application number CN201910773775.5 discloses a screening method of single bacteria of dopamine-promoting components. The application number CN201910257075.0 discloses a recombinant engineering bacterium for producing dopamine by catalyzing substrate dopa. Application number CN201911397692.7 discloses a strain of Escherichia coli for efficiently producing glutamic acid. The application numbers CN202010147933.9, CN201310361804.X and CN202010227468.X respectively disclose a recombinant corynebacterium glutamicum for efficiently producing L-glutamic acid. Most of the microorganisms mentioned above can be used as food or feed and additives therefor. However, these microorganisms produce a relatively single neurotransmitter, and only one neurotransmitter is produced. If these microorganisms are used in co-culture to produce a plurality of neurotransmitters, antagonism may exist between these microorganisms, thereby failing to achieve the effect of producing a plurality of neurotransmitters. In addition, some microorganisms (lactic acid bacteria, etc.) have poor in vitro viability, are intolerant to gastric acid and bile acid, and cannot simultaneously produce neurotransmitters such as gamma-aminobutyric acid, glutamic acid, dopamine, choline, etc. in the intestinal tract, thus limiting the application thereof. Thus, it is a new challenge to obtain probiotics that are more active and are capable of producing multiple neurotransmitters simultaneously.
Disclosure of Invention
The invention aims to provide clostridium butyricum capable of producing various neurotransmitters, and the functional probiotics metabolite is rich in not only gamma-aminobutyric acid, but also various neurotransmitters such as dopamine, glutamic acid, choline, L-tryptophan (5-hydroxytryptamine precursor), tyrosine, taurine, acetylcholine, tyramine and the like.
It is a further object of the present invention to provide the use of clostridium butyricum as described above, including in particular in the production of neurotransmitters, in the preparation of pharmaceuticals, in the preparation of veterinary drugs, feed additives or in the preparation of micro-ecological preparations.
A third object of the present invention is to provide a pharmaceutical, veterinary, feed additive or microecological preparation comprising the clostridium butyricum described above.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the invention provides clostridium butyricum, which is classified and named as clostridium butyricum (Clostridium butyricum) F06, and has a preservation number of CCTCC NO: M2019962F06. The clostridium butyricum belongs to the family of bacillus, genus clostridium and species clostridium butyricum.
The clostridium butyricum is a strain which is used for screening neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like from intestinal contents of healthy carps by an anaerobic culture method by applying an improved RCM culture medium, and the functional probiotics metabolite is rich in not only gamma-aminobutyric acid, but also dopamine, glutamic acid, choline and L-tryptophan (5-hydroxytryptamine precursor), tyrosine, taurine, acetylcholine, tyramine and the like. Clostridium butyricum cctccc NO: m2019962, the colony is round and cloudy white. The microscopic thallus is in a short rod shape, gram positive, spore and spore oval. The 16S rDNA electrophoresis and sequencing analysis show that the homology of clostridium butyricum F06 and the 16S rDNA of clostridium butyricum (CP016332.1CP013352.1LN828942.1LN828931.1AB687551.1NR113244.1X68177.1) reaches 100 percent.
Clostridium butyricum, also known as Clostridium butyricum, clostridium butyricum. Clostridium butyricum belongs to the family Bacillus, genus Clostridium, G + The endophytic spore can resist gastric acid and bile acid and can resist adverse environment. The clostridium butyricum can be widely applied to the fields of medicines, veterinary medicines, feed additives, microecologics and the like.
The clostridium butyricum is preserved, and the preserved strain is: clostridium butyricum (Clostridium butyricum) F06, accession number: cctccc NO: m2019962, date of preservation: 11 months and 20 days in 2019, preservation unit: china Center for Type Culture Collection (CCTCC), preservation address: university of Chinese Wuhan, wuhan (university of Wuhan, hubei province, wuhan and Wuhan university of mountain Lopa nationality).
It is understood that neurotransmitters are collectively referred to herein as neurotransmitters and neurotransmitter precursors.
The invention provides the use of the clostridium butyricum described above for the production of neurotransmitters, which are neurotransmitters and/or neurotransmitter precursors.
In particular, the clostridium butyricum is used for producing neurotransmitter substances, wherein the neurotransmitter substances comprise one or any combination of gamma-aminobutyric acid, dopamine, glutamic acid, acetylcholine, choline, L-tryptophan, L-tyrosine, taurine and tyramine.
Further, the use of clostridium butyricum as described above for the production of neurotransmitters, including gamma-aminobutyric acid, dopamine, glutamate, choline, L-tryptophan and L-tyrosine. Still further, the gamma-aminobutyric acid, dopamine, glutamic acid, choline, L-tryptophan, L-tyrosine and tyramine.
Further, the neurotransmitters include gamma-aminobutyric acid, dopamine, glutamic acid, acetylcholine, choline, L-tryptophan (5-hydroxytryptamine precursor), L-tyrosine, and taurine.
Further, the neurotransmitters include gamma-aminobutyric acid, dopamine, glutamic acid and choline.
Specifically, the preservation number is CCTCC NO: clostridium butyricum of M2019962 was inoculated into the medium for fermentative production of neurotransmitters.
Furthermore, the invention optimizes the culture medium components and fermentation conditions for producing neurotransmitters by clostridium butyricum fermentation.
Preferably, the culture medium includes a seed medium and a fermentation medium. Wherein, the seed culture medium comprises the following components with the following concentration (g/L): glucose 25, soybean meal 10, corn steep liquor 30, sodium glutamate 10, potassium dihydrogen phosphate 1.5, magnesium sulfate 0.2, ammonium sulfate 0.2, disodium hydrogen phosphate 0.5 and calcium carbonate 0.3. The fermentation medium comprises the following components in the following concentration (g/L): glucose 140, soybean meal 15, corn steep liquor 40, magnesium sulfate 0.5, ammonium sulfate 0.2, monopotassium phosphate 0.5, disodium hydrogen phosphate 0.5 and calcium carbonate 0.3.
Preferably, the fermentation conditions are: the pH is 6.8-7.4, the temperature is 22-45 ℃, the inoculation amount is 1-10%, and the culture time is 12-36 h.
Further preferred, optimal fermentation conditions: the pH was 7.2, the temperature was 35 ℃, the inoculum size was 4%, and the incubation time was 24h.
The invention provides application of clostridium butyricum in preparation of medicines.
The invention provides a method for preparing the composite material, which comprises the following steps of: m2019962 Clostridium butyricum F06.
The invention provides application of clostridium butyricum F06 in preparation of veterinary drugs, feed additives or microecological preparations.
The invention provides a method for preparing the composite material, which comprises the following steps of: veterinary drug of clostridium butyricum F06 of M2019962.
The invention provides a method for preparing the composite material, which comprises the following steps of: clostridium butyricum F06 feed additive M2019962.
The invention provides a method for preparing the composite material, which comprises the following steps of: a probiotic of clostridium butyricum F06 of M2019962.
The invention has the beneficial effects that:
the invention uses an improved RCM culture medium, and screens out a strain with high yield of neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like from intestinal contents of healthy carps by an anaerobic culture method: clostridium butyricum F06 (CCTCC No: M2019962). Compared with lactic acid bacteria for producing single neurotransmitter substances, the clostridium butyricum provided by the invention has the following characteristics: 1) Is bacillus, has strong stress resistance and can resist the actions of gastric acid and bile acid; 2) Anaerobic bacteria grow and reproduce in colon or cecum, and do not contend with host for nutrition; 3) Metabolites are rich in a variety of neurotransmitters including gamma-aminobutyric acid, dopamine, glutamic acid, choline, L-tryptophan (5-hydroxytryptamine precursor), L-tyrosine, taurine, etc.; in addition, the clostridium butyricum provided by the invention is different from the conventional clostridium butyricum, and the metabolic product of the conventional clostridium butyricum is butyric acid, and the metabolic product of clostridium butyricum provided by the invention not only comprises butyric acid, but also is rich in neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline, L-tryptophan (5-hydroxytryptamine precursor), L-tyrosine, taurine and the like. Experiments prove that after fermentation conditions of the strain are optimized, the content of neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like in fermentation liquor of the strain reaches 4.78g/L,5.82g/L,135.9g/L and 3.78g/L respectively, and the strain can be widely applied to the fields of feed additives, veterinary medicines, whole field probiotics and the like and has wide application prospects.
Drawings
FIG. 1 is a graph of Clostridium butyricum F06 colonies;
FIG. 2 is a staining microscopic image of Clostridium butyricum F06;
FIG. 3 is a graph showing the content of neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like in clostridium butyricum F06 fermentation broth at different time points;
FIG. 4 is a graph showing the content of gamma-aminobutyric acid, dopamine, glutamic acid, choline and other neurotransmitters in clostridium butyricum F06 fermentation broth at different pH, temperature and inoculum size;
FIG. 5 shows the content of neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid and choline in clostridium butyricum F06 fermentation broth at different temperatures;
FIG. 6 is a graph showing the content of neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like in clostridium butyricum F06 fermentation broth at different inoculum sizes;
FIG. 7 shows the content of neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid and choline in fermentation broth after optimization of clostridium butyricum F06 fermentation conditions.
Detailed Description
The invention is further described in connection with the following detailed description, but the scope of the invention is not limited thereto; the equipment and reagents used in the examples were all conventionally commercially available unless otherwise specified.
Example 1 screening and identification of Clostridium butyricum F06
1. Screening of clostridium butyricum for the production of various neurotransmitters:
the media involved in the screening were as follows:
1) Modified RCM liquid screening media, 1000mL, contained: 10g of tryptone; 10g of beef extract; 3g of yeast extract; glucose 5g; 1g of soluble starch; 5g of sodium chloride; 3g of sodium acetate; 0.5g of L-cysteine;
3g of sodium glutamate; 0.02g of polymyxin B; 6% yeast extract powder; 1.74% ferrous sulfate; 0.37% dipotassium hydrogen phosphate; 0.2% sodium chloride; 0.024% magnesium sulfate.
2) Modified RCM solid screening media: 1000mL of modified RCM broth was added with 15g agar.
3) The modified enhanced clostridium medium, 1000mL, contains: 10g of protein; 10g of beef extract; 3g of yeast powder;
glucose 5g; 1g of soluble starch; 5g of sodium chloride; 0.5g of L-cysteine; 3g of sodium glutamate; 15g of agar;
pH7.0-7.2。
4) Improved enhanced clostridium solid media: 1000mL of modified enhanced Clostridium medium was added with 15g of agar.
5) Seed fermentation medium, 1000mL contains: glucose 25g; 10g of soybean meal; 30g of corn steep liquor; 10g of sodium glutamate;
1.5g of monopotassium phosphate; 0.2g of magnesium sulfate; 0.2g of ammonium sulfate; disodium hydrogen phosphate 0.5g; 0.3g of calcium carbonate.
All media were sterilized at high temperature and pressure (121 ℃, 1X 105 kPa).
The specific screening steps are as follows:
1) The intestinal contents of healthy carp in the Henan province area of yellow river are weighed 5g, and 1:4, adding the strain into sterile physiological saline, and placing the strain in a water bath at 70 ℃ for 15 minutes for preliminary screening to kill part of non-spore bacteria;
2) Then 5mL of culture solution is extracted and transferred into 100mL of modified RCM liquid culture medium, and anaerobic culture is carried out for 48h under the conditions of 37 ℃ and 180 rpm;
3) Extracting 5mL of the culture solution into 100mL of modified reinforced clostridium liquid culture medium, and selectively enriching and culturing for 48h under the anaerobic condition at 37 ℃;
4) Extracting 100uL of culture solution for gradient dilution, then selecting proper dilution gradients to be respectively coated in modified reinforced clostridium solid medium plates, placing in an anaerobic incubator, and culturing for 48 hours at 37 ℃;
5) Selecting a gram-positive strain with colony morphology, culture characteristics, biochemical characteristics and microscopic morphology which all meet the culture characteristics of clostridium butyricum for subsequent experiments;
6) And (3) fermenting and culturing the strain conforming to the culturing characteristics of clostridium butyricum for 24 hours by a seed fermentation medium, centrifuging a fermentation liquid (4 ℃,12000r/min,10 min) to obtain a supernatant, measuring the content of gamma-aminobutyric acid, dopamine, choline and other neurotransmitters in the fermentation supernatant by adopting a high performance liquid chromatography, screening out the strain with the strongest neurotransmitter production capacity, and storing.
2. Identification of clostridium butyricum
1) Morphological and physiological Biochemical characterization
According to the experimental method in the common bacteria system identification manual, the strain with the strongest neurotransmitter substance capability of producing gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like is identified in morphological characteristics and physiological and biochemical characteristics.
2) 16S rDNA sequence analysis
The total DNA of the genome was extracted, and the 16S rRNA fragment of the strain was amplified using the 16S rRNA universal primers 27F,5 '-AGAGTTTGATCCTGGGCTCAG-3' and 1492R,5 '-TACGGCTACCTTGTTACGAC-3'.
The PCR reaction system (25. Mu.L) was: 2 XTaq Mix 12.5. Mu.L, upstream primer 27F (10. Mu. Mol/L) 1. Mu.L, downstream primer 1492R (10. Mu. Mol/L) 1. Mu.L, bacterial DNA 2.5. Mu.L, and sterile water 8. Mu.L.
The PCR reaction procedure was: pre-denaturation at 94℃for 5min; denaturation at 94℃for 30s, annealing at 58℃for 30s, extension at 72℃for 50s,28 cycles; extending at 72℃for 10min.
The PCR product was subjected to 2% TAE agarose gel electrophoresis, and the size of the PCR product was detected, and then the 16S rDNA gene product was submitted to Shanghai Bioengineering Co. The sequencing results were BLAST against GenBank databases in NCBI and the phylogenetic tree was constructed to analyze sequence homology.
3. Results and analysis
The 12 strains which meet the culture characteristics of clostridium butyricum are screened out, seed fermentation broths of the 12 strains are respectively detected for the capability of producing neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid and choline, and the result shows that the 6 strain has the strongest capability of producing neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid and choline. Thus strain 06 was selected for subsequent experiments and designated clostridium butyricum F06. Clostridium butyricum cctccc NO: m2019962, colony (FIG. 1) was round and cloudy white. Microscopic examination (FIG. 2) shows that the thallus is in a short rod shape, gram positive, spore and oval.
The 16S rDNA gene sequence of the strain F06 is obtained through PCR amplification, sequencing is carried out on NCBI by using Blast comparison, related sequences are obtained from a GenBank database and are subjected to phylogenetic analysis, and the sequencing result is shown in SEQ ID NO.1. The result shows that the homology of the strain F06 and the 16S rDNA of clostridium butyricum (CP016332.1CP013352.1LN828942.1LN828931.1AB687551.1NR113244.1X68177.1) reaches 100 percent, and the strain F06 is judged to be clostridium and named clostridium butyricum F06 by combining physiological and biochemical characteristics.
The above results show that clostridium butyricum F06 can produce neurotransmitters such as gamma-aminobutyric acid, dopamine, glutamic acid, choline and the like in high yield, so that the clostridium butyricum F06 is preserved in China Center for Type Culture Collection (CCTCC) for 11 months and 20 days in 2019, with the preservation number: CCTCCNO: m2019962, deposit address: university of Chinese Wuhan, wuhan (university of Wuhan, hubei province, wuhan and Wuhan university of mountain Lopa nationality).
EXAMPLE 2 use of Clostridium butyricum F06 for the production of neurotransmitters
This example provides the use of clostridium butyricum of example 1 for the production of neurotransmitters, including gamma-aminobutyric acid, dopamine, glutamate and choline.
1. Clostridium butyricum F06 growth curve assay
Clostridium butyricum F06, which is the strain with the strongest neurotransmitter-producing ability and stored in the laboratory, is inoculated into a modified RCM solid medium, subjected to stationary culture at 37 ℃ under anaerobic conditions for 24 hours, and then the activated strain is inoculated into the modified enhanced Clostridium culture medium at 37 ℃ and 180rpm, and cultured overnight under anaerobic conditions as a seed solution.
6 test tubes containing 3.9mL of RCM medium were taken and the incubation times were marked with markers, namely 0, 4, 8, 12, 24, 48h. 100. Mu.L of seed solution was accurately aspirated each time using a pipette, and inoculated into 6 numbered tubes, respectively. Anaerobic stationary culture at 37 deg.C after inoculation, taking out test tubes numbered as corresponding time at 0, 4, 8, 12, 24 and 48 hr respectively, and immediately storing in refrigerator.
Finally, the non-inoculated RCM liquid culture medium is used as a blank control, and the 600nm wavelength is selected for photoelectric turbidimetry to determine the growth curve of clostridium butyricum F06. And detecting the content of neurotransmitters such as gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu) and Choline (Choline) at each time point by using high performance liquid chromatography.
As a result, as shown in FIG. 3, the number of colonies was measured at 24 hours, and the content of neurotransmitters such as gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu) and Choline (Choline) was maximized.
2. Determination of optimal pH, temperature and inoculum size of clostridium butyricum F06 fermentation medium
The initial pH of the seed culture medium was adjusted to 6.8, 7.0, 7.2, 7.4, 7.6 and 7.8 with 4mol/L HCl and 20% NaOH solution, respectively, and 2% seed solution was added thereto, and the culture was performed under anaerobic conditions at 37℃and 180rpm for 24 hours. The number of bacteria was measured by the hemocytometer method. 2% Clostridium butyricum F06 bacteria solution was inoculated into 100mL of modified RCM medium, and cultured at constant temperature of 30℃at 37℃at 40℃and at 45℃at 180rpm, respectively, for 24 hours under anaerobic conditions. After inoculating clostridium butyricum F06 seed solution at 0.5%, 1%, 2%, 4%, 6% and 8%, culturing was performed under anaerobic conditions at 37 ℃,180rpm for 24 hours. Then, the colony count and the content of neurotransmitters such as gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu), choline (Choline) and the like under the conditions of pH, temperature and inoculum size are respectively measured by a blood cell count method and a high performance liquid chromatography method.
The results are shown in FIG. 4, FIG. 5 and FIG. 6, and the optimal culture conditions are as follows: the pH was 7.4, the temperature was 37℃and the inoculum size was 4%, and the number of colonies was measured at 24 hours for the culture, and the amounts of neurotransmitters such as gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu) and Choline (Choline) were the largest.
3. Optimization of Clostridium butyricum F06 Medium composition
Glucose, soybean meal, corn steep liquor are the main components affecting the culture medium. Thus, test design L16 (3 4 ) Orthogonal experiments, which determine the components of clostridium butyricum F06 medium, were designed as follows: glucose (100 g,120g,140 g), soybean meal (10 g,15g,20 g), corn steep liquor (20 g,30g,40 g). Then, the colony number and the content of neurotransmitters such as gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu) and Choline (Choline) under the conditions of various components are respectively measured by a blood cell count method and a high performance liquid chromatography method.
TABLE 1 results of the influence of the orthogonal Medium composition test on GABA content
Note that: the ia value reflects the effect of levels of each factor B, C of 1, 2, 3 on A1 level (A, B, C stands for glucose, soybean meal, corn meal, respectively). Similarly, IA reflects the effect of three levels of each factor B, C on A2 (A3) levels once each. When comparing the differences between IA, IIA, IIIA, the effect of B, C on IA, IIA, IIIA can be considered to be substantially identical. Thus, the difference between IA, IIA, IIIA can be seen as being due to factor A taking three different levels. According to this method, IB, IIB, IIIB and IC, IIC, IIIC can be calculated. The difference between the maximum and minimum values in each of columns I, II, III is then calculated and is the very difference, designated R. The range of each column reflects the magnitude of the effect of the selected level variation of the factor corresponding to that column on GABA content. The greater the value, the greater the extent to which the factor affects GABA content. Tables 2, 3 and 4 are the same.
TABLE 2 results of the influence of the orthogonal Medium composition experiments on Glu content
TABLE 3 results of the influence of the orthogonal Medium composition test on DA content
| Numbering device | Glucose (g) | Bean pulp (g) | Corn flour (g) | DA content (g) |
| 1 | 100 | 10 | 20 | 3.89 |
| 2 | 100 | 15 | 30 | 4.38 |
| 3 | 100 | 20 | 40 | 5.14 |
| 4 | 120 | 10 | 30 | 5.24 |
| 5 | 120 | 15 | 40 | 3.86 |
| 6 | 120 | 20 | 20 | 4.26 |
| 7 | 140 | 10 | 40 | 4.32 |
| 8 | 140 | 15 | 20 | 5.08 |
| 9 | 140 | 20 | 30 | 3.69 |
| Ⅰ | 13.41 | 12.07 | 13.23 | |
| Ⅱ | 13.36 | 13.32 | 13.31 | |
| Ⅲ | 13.09 | 13.09 | 13.32 | |
| R | 0.32 | 1.02 | 0.09 |
TABLE 4 results of the influence of orthogonal Medium composition experiments on Choline content
The results are shown in tables 1 to 4, and clostridium butyricum F06 contained 140g of glucose in the medium; bean pulp, 15g; corn flour, 20g; the culture conditions were pH 7.4, the temperature was 37℃and the inoculum size was 4%, and the maximum gamma-aminobutyric acid (GABA) content was measured at 24 hours of the culture (Table 1). Clostridium butyricum F06 in the medium composition of glucose, 140g; bean pulp, 20g; corn flour, 30g; the culture conditions were pH 7.4, the temperature was 37℃and the inoculum size was 4%, and the maximum glutamic acid (Glu) content was measured at 24 hours of culture (Table 2). Clostridium butyricum F06 in the medium composition of glucose, 130g; 10g of soybean meal; corn flour, 30g; the cultivation conditions were pH 7.4, the temperature was 37℃and the inoculum size was 4%, and the maximum Dopamine (DA) content was measured for 24 hours (Table 3). Clostridium butyricum F06 in the medium composition of glucose, 140g; 10g of soybean meal; corn flour, 40g; the cultivation conditions were pH 7.4, temperature 37℃and inoculum size 4%, and the maximum Choline (Choline) content was measured at 24 hours. Since the above results are that the combination under laboratory conditions has not been subjected to production practice, further experiments have been carried out to verify the colony count of clostridium butyricum F06 and the content of the related neurotransmitters under the combination conditions. From tables 1 to 4, it is understood that the main component affecting GABA content is glucose, the main component affecting Glu content is glucose, the main component affecting DA content is soybean meal, and the main component affecting Choline content is corn starch. Therefore, in consideration of test results and production cost, clostridium butyricum F06 is selected to be 140g of glucose in the culture medium; bean pulp, 15g; corn flour, 40g; the culture condition is that the pH is 7.4, the temperature is 37 ℃, the inoculation amount is 4 percent, and the neurotransmitter content in the fermentation broth is detected when the culture time is 24 hours. As can be seen from FIG. 7, the content of gamma-aminobutyric acid, glutamic acid, dopamine and choline in clostridium butyricum fermentation broth measured under the conditions reached 4.78g,135.9g,5.82g and 3.78g/L, respectively.
EXAMPLE 3 Clostridium butyricum F06 simulated gut fermentation product metabonomics analysis
This example the specific test method for the analysis of the metabonomics of the simulated gut fermentation products of clostridium butyricum F06 provided in example 1 is as follows:
after inoculation of the fermentation broth with clostridium butyricum F06, samples were taken at 2, 4, 6, 8, 12, 24 hours, numbered A, B, C, D, E, F in sequence. Then, non-targeted metabonomics analysis based on ultra-high performance liquid chromatography-Q-TOF MS is carried out to obtain primary mass spectrum and secondary mass spectrum data, and XCMS is adopted to carry out peak extraction and metabolite identification on the data.
In the test results, A, B, C, D (2, 4, 6, 8 hours) samples, i.e. during clostridium butyricum F06 breeding season: the transmitters related to the nervous system signal transmission, such as gamma-aminobutyric acid, dopamine, glutamic acid, acetylcholine, choline, L-tryptophan, L-tyrosine, tyramine, taurine and the like are obviously rich. The test results are shown in Table 5.
TABLE 5 results of metabonomic analysis of clostridium butyricum F06 simulated digestive tract fermentation products
Note that: mzmed is the median of m/z, the intermediate number of mass to charge ratios. rtmed is median of retention time, the median of the retention times, which together with mzmed is characteristic of this substance. POS a, B, C, D, E, F represent the analysis results in positive ion mode at 2, 4, 6, 8, 12, 24 hours, respectively (POS is an abbreviation for positive, i.e. positive ion or positive).
Example 4
This example is the use of clostridium butyricum as described in example 1 in the preparation of a medicament.
In practical application, the medicines comprise the components with the preservation number of CCTCC NO: clostridium butyricum of M2019962.
And (3) setting the preservation number as CCTCC NO: clostridium butyricum of M2019962 fed mice, the test was set to 4 groups (negative control group, low dose 5000CFU, medium dose 10000CFU and high dose 50000CFU, respectively), each group being repeated 10 times. After 1 week of continuous feeding, the heart was sampled and plasma was isolated. Based on LC-MS/GC-MS technology, targeted metabonomics analysis is carried out, and the feeding preservation number is CCTCC NO: m2019962 Clostridium butyricum mice contained higher levels of gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu), choline (Choline), L-tryptophan, L-tyrosine, taurine, acetylcholine and tyramine in the plasma than mice without the addition of the bacteria.
Example 5
This example is the use of clostridium butyricum as described in example 1 in the preparation of veterinary drugs, feed additives or microecologics.
In practical application, the veterinary drug, the feed additive and the microecological preparation all comprise the components with the preservation number of CCTCC NO: clostridium butyricum F06 of M2019962.
And (3) setting the preservation number as CCTCC NO: clostridium butyricum F06 of M2019962 is fed to broilers and pigs, and targeted metabonomics analysis detects the content level of gamma-aminobutyric acid (GABA), dopamine (DA), glutamic acid (Glu), choline (Choline), L-tryptophan, L-tyrosine, taurine, acetylcholine and tyramine in blood, and finds that the feeding and preserving number is cctccc NO: both chickens and pigs of clostridium butyricum F06 of M2019962 had higher blood levels than were not fed with this bacterium.
<110> Henan agricultural university
<120> Clostridium butyricum and its application, medicine, food, health product, veterinary drug, feed additive, and microecological preparation
<160> 1
<170> PatentIn version 3.5
<211> 1415
<212> DNA
<213> Clostridium butyricum
<221> 16s rDNA
<400> 1
gagtttgatc ctggctcagg acgaacgctg gcggcgtgct taacacatgc aagtcgagcg 60
atgaagctcc ttcgggagtg gattagcggc ggacgggtga gtaacacgtg ggtaacctgc 120
ctcatagagg ggaatagcct ttcgaaagga agattaatac cgcataagat tgtagtaccg 180
catggtacag caattaaagg agtaatccgc tatgagatgg acccgcgtcg cattagctag 240
ttggtgaggt aacggctcac caaggcgacg atgcgtagcc gacctgagag ggtgatcggc 300
cacattggga ctgagacacg gcccagactc ctacgggagg cagcagtggg gaatattgca 360
caatggggga aaccctgatg cagcaacgcc gcgtgagtga tgacggtctt cggattgtaa 420
agctctgtct ttagggacga taatgacggt acctaaggag gaagccacgg ctaactacgt 480
gccagcagcc gcggtaatac gtaggtggca agcgttgtcc ggatttactg ggcgtaaagg 540
gagcgtaggt ggatatttaa gtgggatgtg aaatacccgg gcttaacctg ggtgctgcat 600
tccaaactgg atatctagag tgcaggagag gaaaggagaa ttcctagtgt agcggtgaaa 660
tgcgtagaga ttaggaagaa taccagtggc gaaggcgcct ttctggactg taactgacac 720
tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgccgtaaa 780
cgatgaatac taggtgtagg ggttgtcatg acctctgtgc cgccgctaac gcattaagta 840
ttccgcctgg ggagtacggt cgcaagatta aaactcaaag gaattgacgg gggcccgcac 900
aagcagcgga gcatgtggtt taattcgaag caacgcgaag aaccttacct agacttgaca 960
tctcctgaat tactctgtaa tggaggaagc cacttcggtg gcaggaagac aggtggtgca 1020
tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct 1080
tattgttagt tgctaccatt tagttgagca ctctagcgag actgcccggg ttaaccggga 1140
ggaaggtggg gatgacgtca aatcatcatg ccccttatgt ctagggctac acacgtgcta 1200
caatggtcgg tacaatgaga tgcaacctcg cgagagtgag caaaactata aaaccgatct 1260
cagttcggat tgtaggctga aactcgccta catgaagctg gagttgctag taatcgcgaa 1320
tcagaatgtc gcggtgaata cgttcccggg ccttgtacac accgcccgtc acaccatgag 1380
agttggcaat acccaaagtt cgtgagctaa ccgca 1415
Claims (8)
1. A clostridium butyricum is characterized in that the clostridium butyricum is classified and named clostridium butyricum @Clostridium butyricum) F06, the preservation number is CCTCC NO: m2019962.
2. The use of clostridium butyricum according to claim 1 for the production of neurotransmitters, wherein the neurotransmitters comprise one or any combination of gamma-aminobutyric acid, dopamine, glutamic acid, acetylcholine, choline, L-tryptophan, L-tyrosine, taurine, tyramine.
3. The use of clostridium butyricum according to claim 2 for the production of neurotransmitters, comprising gamma-aminobutyric acid, dopamine, glutamic acid, acetylcholine, choline, L-tryptophan, L-tyrosine, tyramine.
4. Use of clostridium butyricum according to claim 2 for the production of neurotransmitters, including gamma aminobutyric acid, dopamine, glutamate, choline.
5. Use of clostridium butyricum according to claim 1 for the preparation of a medicament.
6. A pharmaceutical product comprising clostridium butyricum as claimed in claim 1.
7. Use of clostridium butyricum according to claim 1 for the preparation of veterinary or microecological formulations.
8. A veterinary or probiotic formulation comprising clostridium butyricum as claimed in claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011383439 | 2020-11-30 | ||
| CN2020113834399 | 2020-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113832069A CN113832069A (en) | 2021-12-24 |
| CN113832069B true CN113832069B (en) | 2024-01-30 |
Family
ID=78969022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111200171.5A Active CN113832069B (en) | 2020-11-30 | 2021-10-14 | Clostridium butyricum and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113832069B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012350A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic clostridium butyricum strain |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
| CN108137657A (en) * | 2015-10-02 | 2018-06-08 | 益普生生物制药有限公司 | The method for purifying clostridial neurotoxins |
| CN109415750A (en) * | 2016-07-01 | 2019-03-01 | 益普生生物制药有限公司 | The production of the clostridial neurotoxins of activation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| RS61872B1 (en) * | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
-
2021
- 2021-10-14 CN CN202111200171.5A patent/CN113832069B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012350A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic clostridium butyricum strain |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
| CN108137657A (en) * | 2015-10-02 | 2018-06-08 | 益普生生物制药有限公司 | The method for purifying clostridial neurotoxins |
| CN109415750A (en) * | 2016-07-01 | 2019-03-01 | 益普生生物制药有限公司 | The production of the clostridial neurotoxins of activation |
Non-Patent Citations (4)
| Title |
|---|
| Guangtian Cao et al..Positive effects of a Clostridium butyricum-based compound probiotic on growth performance, immune responses, intestinal morphology, hypothalamic neurotransmitters, and colonic microbiota in weaned piglets.《Food & function》.2019,第10卷(第5期),2926-2934. * |
| Laipeng Xu et al..Dietary supplementation with Clostridium butyricum improves growth performance of broilers by regulating intestinal microbiota and mucosal epithelial cells.《Animal Nutrition》.2021,第7卷(第4期),1105-1114. * |
| Magdalena K. Stoeva et al..Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease.《Gut Microbes》.2021,第13卷(第1期),1-28. * |
| 徐翡 等.丁酸梭菌及其在生猪养殖中的应用研究.《家畜生态学报》.2023,第44卷(第2期),85-91. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113832069A (en) | 2021-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6913033B2 (en) | Gas fermentation for protein or feed production | |
| CN105105145B (en) | Lactobacillus plantarum and application thereof in preparation of functional food for reducing blood sugar and blood fat | |
| CN108373984A (en) | A kind of Lactobacillus paracasei and its application | |
| CN109182171B (en) | Mutagenic strain for high yield of gamma-aminobutyric acid and biological preparation thereof | |
| CN114854643B (en) | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof | |
| CN110747146B (en) | Lactobacillus gasseri LG08 with uric acid degradation effect and application thereof | |
| CN106957810A (en) | A kind of Pediococcus acidilactici and application thereof | |
| CN116656578B (en) | Lactobacillus mucilaginosus VB216 and application thereof | |
| CN109943510A (en) | One plant of lactic acid bacillus DU-106 and its application with probiotic properties | |
| CN115094012A (en) | Preparation method and application of bacillus coagulans BC-HYC strain microbial inoculum | |
| CN113403227A (en) | Lactobacillus plantarum and preparation method and application thereof | |
| Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
| CN110257302B (en) | Screening method and application of lactobacillus strain with antioxidant capacity | |
| CN108522884A (en) | A kind of compound micro-ecological preparation is used to prevent the purposes of broiler chicken fat deposition | |
| Lee et al. | Bacillus amyloliquefaciens CU33 fermented feather meal-soybean meal product improves the intestinal morphology to promote the growth performance of broilers | |
| CN116694539B (en) | Lactobacillus plantarum J26 as direct vat set starter, and preparation method and application thereof | |
| CN113337427A (en) | Lactobacillus plantarum HNU082, composition and application thereof | |
| CN113832069B (en) | Clostridium butyricum and application thereof | |
| CN112708590A (en) | Composition for promoting growth of Achiminotropic bacteria and application thereof | |
| CN117025452A (en) | High-density culture method of bifidobacterium longum subspecies infantis B2-01 | |
| CN116064313A (en) | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue | |
| CN112961808A (en) | Lipid-lowering and weight-losing bifidobacterium lactis preparation and preparation method thereof | |
| JP2016533755A5 (en) | ||
| CN117143770B (en) | Wettman coagulans GLM336 and application thereof | |
| CN116656526B (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |